Table of Content




1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET SCOPE 17
1.2.1 MARKETS COVERED 17
1.2.2 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 18
1.4 LIMITATIONS 18
1.5 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 22
2.1.2.2 Breakdown of primary sources 22
2.2 MARKET SIZE ESTIMATION 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.4 MARKET SHARE ESTIMATION 27
2.5 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 31
4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW 31
4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019) 32
4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET 33
4.4 PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS 34

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
5.2.1 DRIVERS 43
5.2.1.1 Increasing adoption of immunotherapy drugs over conventional treatment regimens 43
5.2.1.2 Rising prevalence of cancer and autoimmune & infectious diseases 43
5.2.1.3 Increasing demand for monoclonal antibodies and biosimilars 44
?
5.2.2 RESTRAINTS 45
5.2.2.1 Timeline issues, side-effects, and manufacturing complexities 45
5.2.2.2 High attrition rate in the product development cycle 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Increased demand for personalized medicines 46
5.2.3.2 High scope for growth in emerging economies 46
5.2.3.3 Development of affordable nanoparticles for deploying immunotherapies 47
5.2.4 CHALLENGES 47
5.2.4.1 High cost of immunotherapy treatment, regional disparities, and lack of insurance coverage 47
5.2.4.2 Side-effects and low efficacy of immunotherapy drugs 48
5.2.4.3 Lack of awareness 49
5.2.4.4 Delays in diagnosis and treatment 49
5.2.5 IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY
DRUGS MARKET 50

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE 51
6.1 INTRODUCTION 52
6.2 MONOCLONAL ANTIBODIES 52
6.2.1 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019 52
6.3 CHECKPOINT INHIBITORS 53
6.3.1 CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS 53
6.4 INTERFERONS & INTERLEUKINS 54
6.4.1 INTERFERONS & INTERLEUKINS USE THE PATIENT’S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS 54
6.5 OTHER IMMUNOTHERAPIES 55

7 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 57
7.1 INTRODUCTION 58
7.2 CANCER 58
7.2.1 MALIGNANT CANCERS 59
7.2.1.1 Malignant cancers held the largest share of the immunotherapy drugs market in 2019 59
7.2.2 BENIGN CANCERS 60
7.2.2.1 Availability of a range of drugs for benign cancer treatment supports market growth 60
7.3 AUTOIMMUNE & INFLAMMATORY DISEASES 61
7.3.1 STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT 61
7.4 INFECTIOUS DISEASES 62
7.4.1 INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH 62
7.5 OTHER THERAPEUTIC AREAS 63

8 IMMUNOTHERAPY DRUGS MARKET, BY END USER 64
8.1 INTRODUCTION 65
8.2 HOSPITALS 65
8.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET 65
8.3 CLINICS 66
8.3.1 CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS 66
8.4 OTHER END USERS 67

9 IMMUNOTHERAPY DRUGS MARKET, BY REGION 68
9.1 INTRODUCTION 69
9.2 NORTH AMERICA 70
9.2.1 US 73
9.2.1.1 US holds the largest share of the North American market 73
9.2.2 CANADA 75
9.2.2.1 Increasing prevalence of cancer and the growing availability of approved immunotherapy drugs to drive market growth 75
9.3 EUROPE 77
9.3.1 UK 79
9.3.1.1 The UK accounts for the largest share of the European market 79
9.3.2 GERMANY 80
9.3.2.1 New law for biosimilars in Germany to drive market growth 80
9.3.3 FRANCE 82
9.3.3.1 Initiatives by leading pharma players to drive the French market for immunotherapy drugs 82
9.3.4 ITALY 84
9.3.4.1 Availability of reimbursement drives the market in Italy 84
9.3.5 SPAIN 85
9.3.5.1 Increasing incidences of cancer to drive market growth during the forecast period 85
9.3.6 REST OF EUROPE 87
9.4 ASIA PACIFIC 89
9.4.1 CHINA 92
9.4.1.1 Rising prevalence of cancer and other infectious diseases to boost the adoption of immunotherapy in China 92
9.4.2 JAPAN 95
9.4.2.1 Universal health coverage boosts the market for immunotherapy drugs in Japan 95
9.4.3 INDIA 96
9.4.3.1 High number of cancer specialty care hospitals to support market growth 96
9.4.4 AUSTRALIA 98
9.4.4.1 Government initiatives to pave the way for the development of the Australian immunotherapy drugs market 98
9.4.5 REST OF ASIA PACIFIC 100
9.5 REST OF THE WORLD 101
9.5.1 MIDDLE EAST & AFRICA 103
9.5.1.1 Infrastructural growth and favorable socioeconomic trends will support market growth in the MEA 103
9.5.2 BRAZIL 105
9.5.2.1 Government support and player interest in Brazil will drive the market 105
9.5.3 REST OF LATIN AMERICA 107

10 COMPETITIVE LANDSCAPE 109
10.1 INTRODUCTION 109
10.2 MARKET EVALUATION FRAMEWORK 109
10.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 110
10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019) 110
10.4.1 STARS 110
10.4.2 EMERGING LEADERS 110
10.4.3 PERVASIVE COMPANIES 110
10.4.4 EMERGING COMPANIES 110
10.5 COMPETITIVE SCENARIO 112
10.5.1 KEY PARTNERSHIPS AND COLLABORATIONS 112
10.5.2 KEY PRODUCT LAUNCHES 113
10.5.3 KEY ACQUISITIONS 113
10.5.4 KEY EXPANSIONS 114

11 COMPANY PROFILES 115
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 F. HOFFMANN-LA ROCHE 115
11.2 PFIZER 120
11.3 MERCK & CO 125
11.4 NOVARTIS INTERNATIONAL AG 130
11.5 JOHNSON & JOHNSON 134
11.6 SANOFI 136
11.7 GLAXOSMITHKLINE 138
11.8 ABBVIE 141
11.9 AMGEN 145
11.10 BOEHRINGER INGELHEIM 149
11.11 ASTRAZENECA 151
11.12 ELI LILLY AND COMPANY 153
11.13 IMMATICS BIOTECHNOLOGIES GMBH 156
11.14 GENMAB 158
11.15 BIONTECH SE 160
11.16 GILEAD SCIENCES 163
11.17 NBE THERAPEUTICS 167
11.18 TEVA PHARMACEUTICALS 167
11.19 BAYER AG 167
11.20 BRISTOL-MYERS SQUIBB 168
11.21 INCYTE CORPORATION 168
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 169
12.1 DISCUSSION GUIDE 169
12.2 KNOWLEDGE STORE 173
12.3 RELATED REPORTS 175
12.4 AUTHOR DETAILS 176



List of Figures



FIGURE 1 RESEARCH DESIGN 19
FIGURE 2 PRIMARY SOURCES 21
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 22
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 23
FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE 23
FIGURE 6 DATA TRIANGULATION METHODOLOGY 26
FIGURE 7 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY TYPE (2020) 28
FIGURE 8 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY THERAPEUTIC AREA 2020 VS. 2025 (USD BILLION) 29
FIGURE 9 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY END USER 2020 VS. 2025 (USD BILLION) 29
FIGURE 10 NORTH AMERICA DOMINATES THE MARKET, BUT APAC TO REGISTER THE HIGHEST GROWTH RATE 30
FIGURE 11 INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS TO DRIVE THE MARKET 31
FIGURE 12 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET IN 2019 32
FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOTHERAPY DRUGS MARKET FROM 2020 TO 2025 33
FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2019 69
FIGURE 16 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT 71
FIGURE 17 APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT 90
FIGURE 18 MARKET EVALUATION FRAMEWORK: COLLABORATIVE EFFORT WAS A PROMINENT TARGET FOR MARKET COMPANIES 109
FIGURE 19 IMMUNOTHERAPY DRUGS MARKET IN 2019 110
FIGURE 20 COMPETITIVE LEADERSHIP MAPPING: IMMUNOTHERAPY DRUGS MARKET 111
FIGURE 21 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019) 115
FIGURE 22 PFIZER: COMPANY SNAPSHOT (2019) 120
FIGURE 23 MERCK & CO: COMPANY SNAPSHOT (2019) 125
FIGURE 24 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2019) 130
FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019) 134
FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019) 136
FIGURE 27 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2019) 138
FIGURE 28 ABBVIE: COMPANY SNAPSHOT (2019) 141
FIGURE 29 AMGEN: COMPANY SNAPSHOT (2019) 145
FIGURE 30 ASTRAZENECA: COMPANY SNAPSHOT (2019) 151
FIGURE 31 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019) 153
FIGURE 32 GENMAB: COMPANY SNAPSHOT (2019) 158
FIGURE 33 BIONTECH SE: COMPANY SNAPSHOT (2019) 160
FIGURE 34 GILEAD SCIENCES: COMPANY SNAPSHOT (2019) 163

 

List of Tables



TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025 43
TABLE 2 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018 46
TABLE 3 COST OF KEYTRUDA, BY REGION (2018) 48
TABLE 4 CHECKPOINT INHIBITORS COVERED BY THE AUSTRALIAN PBS, AS OF JUNE 2019 48
TABLE 5 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 52
TABLE 6 THERAPEUTIC AREAS IN WHICH MONOCLONAL ANTIBODY
THERAPIES ARE APPROVED 53
TABLE 7 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2018–2025 (USD BILLION) 53
TABLE 8 CHECKPOINT INHIBITORS MARKET, BY REGION, 2018–2025(USD BILLION) 54
TABLE 9 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2014–2021 (USD BILLION) 55
TABLE 10 OTHER IMMUNOTHERAPIES MARKET, BY REGION, 2018-2025 (USD BILLION) 56
TABLE 11 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 58
TABLE 12 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION 2018–2025 (USD BILLION) 58
TABLE 13 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 59
TABLE 14 IMMUNOTHERAPY DRUGS MARKET FOR MALIGNANT CANCER, BY REGION 2018–2025 (USD BILLION) 60
TABLE 15 IMMUNOTHERAPY DRUGS MARKET FOR BENIGN CANCER, BY REGION, 2018–2025 (USD BILLION) 60
TABLE 16 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018–2025 (USD BILLION) 61
TABLE 17 IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD BILLION) 62
TABLE 18 IMMUNOTHERAPY DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018–2025 (USD BILLION) 63
TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION) 65
TABLE 20 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION 2018-2025 (USD BILLION) 66
TABLE 21 IMMUNOTHERAPY DRUGS MARKET FOR CLINICS, BY REGION 2018–2025 (USD BILLION) 66
TABLE 22 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION 2018–2025 (USD BILLION) 67
TABLE 23 IMMUNOTHERAPY DRUGS MARKET , BY REGION, 2018–2025 (USD BILLION) 69
TABLE 24 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY 2018–2025 (USD BILLION) 71
TABLE 25 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE 2018–2025 (USD BILLION) 72
TABLE 26 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION) 72
TABLE 27 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION) 72
TABLE 28 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 73
TABLE 29 NEW CANCER CASES AND DEATHS IN THE US, BY TYPE, 2020 73
TABLE 30 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 74
TABLE 31 US: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 74
TABLE 32 US: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 74
TABLE 33 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION) 75
TABLE 34 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 75
TABLE 35 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 76
TABLE 36 CANADA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 76
TABLE 37 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 76
TABLE 38 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY 2018–2025 (USD BILLION) 77
TABLE 39 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 77
TABLE 40 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 78
TABLE 41 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 78
TABLE 42 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 78
TABLE 43 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 79
TABLE 44 UK: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 79
TABLE 45 UK: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 80
TABLE 46 UK: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION) 80
TABLE 47 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE 2018–2025 (USD BILLION) 81
TABLE 48 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 81
TABLE 49 GERMANY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 81
TABLE 50 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 82
TABLE 51 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 82
TABLE 52 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 83
TABLE 53 FRANCE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 83
TABLE 54 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 83
TABLE 55 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 84
TABLE 56 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 84
TABLE 57 ITALY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 85
TABLE 58 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 85
TABLE 59 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 86
TABLE 60 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 86
TABLE 61 SPAIN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 86
TABLE 62 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 87
TABLE 63 ROE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 87
TABLE 64 ROE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 88
TABLE 65 ROE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 88
TABLE 66 ROE: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 88
TABLE 67 APAC: INCREASE IN HEALTH EXPENDITURE, BY COUNTRY (USD PER CAPITA) 89
TABLE 68 APAC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY 2018–2025 (USD BILLION) 91
TABLE 69 APAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 91
TABLE 70 APAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 91
TABLE 71 APAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 92
TABLE 72 APAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 92
TABLE 73 CANCER CASES IN CHINA, 2018 93
TABLE 74 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 93
TABLE 75 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 94
TABLE 76 CHINA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 94
TABLE 77 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 94
TABLE 78 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 95
TABLE 79 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 95
TABLE 80 JAPAN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 96
TABLE 81 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 96
TABLE 82 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 97
TABLE 83 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 97
TABLE 84 INDIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 97
TABLE 85 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 98
TABLE 86 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE 2018–2025 (USD BILLION) 98
TABLE 87 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 99
TABLE 88 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 99
TABLE 89 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 99
TABLE 90 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 100
TABLE 91 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 100
TABLE 92 ROAPAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 101
TABLE 93 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 101
TABLE 94 ROW: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY 2018–2025 (USD BILLION) 101
TABLE 95 ROW: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 102
TABLE 96 ROW: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 102
TABLE 97 ROW: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 102
TABLE 98 ROW: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 103
TABLE 99 MEA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 104
TABLE 100 MEA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 104
TABLE 101 MEA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 104
TABLE 102 MEA: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 105
TABLE 103 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION) 106
TABLE 104 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 106
TABLE 105 BRAZIL: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 106
TABLE 106 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 107
TABLE 107 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY TYPE 2018–2025 (USD BILLION) 107
TABLE 108 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA 2018–2025 (USD BILLION) 108
TABLE 109 ROLATAM: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE 2018–2025 (USD BILLION) 108
TABLE 110 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY END USER 2018–2025 (USD BILLION) 108
TABLE 111 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2016–2019) 112
TABLE 112 PRODUCT LAUNCHES (2016–2019) 113
TABLE 113 ACQUISITIONS (2016–2019) 113
TABLE 114 EXPANSIONS (2016–2019) 114